QCG
ALLO icon

Quadrant Capital Group’s Allogene Therapeutics ALLO Stock Holding History

Quadrant Capital Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,853
Closed -$11.8K – 1291
2026
Q1 		$11.8K Hold
4,853
– – ﹤0.01% 2154
2025
Q4 		$6.65K Buy
+4,853
New +$6.4K ﹤0.01% 2306
2025
Q2 		– Sell
-4,880
Closed -$7.13K – 1374
2025
Q1 		$7.13K Buy
4,880
+4,509
+1,215% +$8.5K ﹤0.01% 2285
2024
Q4 		$791 Sell
371
-389
-51% -$959 ﹤0.01% 2611
2024
Q3 		$2.13K Buy
+760
New +$2.03K ﹤0.01% 2489
2024
Q2 		– Sell
-1,414
Closed -$6.32K – 2701
2024
Q1 		$6.32K Hold
1,414
– – ﹤0.01% 2253
2023
Q4 		$4.54K Sell
1,414
-2,176
-61% -$6.17K ﹤0.01% 2297
2023
Q3 		$11.4K Buy
3,590
+3,104
+639% +$13.6K ﹤0.01% 1941
2023
Q2 		$2.42K Sell
486
-68
-12% -$368 ﹤0.01% 2375
2023
Q1 		$2.74K Buy
554
+518
+1,439% +$3.32K ﹤0.01% 2368
2022
Q4 		$226 Sell
36
-790
-96% -$7.31K ﹤0.01% 2690
2022
Q3 		$9K Hold
826
– – ﹤0.01% 1913
2022
Q2 		$9K Sell
826
-587
-42% -$5.21K ﹤0.01% 1695
2022
Q1 		$13K Buy
1,413
+1,055
+295% +$11K ﹤0.01% 1521
2021
Q4 		$5K Buy
358
+272
+316% +$4.8K ﹤0.01% 1850
2021
Q3 		$2K Buy
86
+78
+975% +$1.85K ﹤0.01% 2099
2021
Q2 		$0 Buy
+8
New +$228 ﹤0.01% 2396

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Quadrant Capital Group's ALLO Position: Q2 2026 in Review

Quadrant Capital Group sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 4,853 shares — an estimated $11.8K sold.

Quadrant Capital Group first reported a position in ALLO in Q2 2021 and held it in 17 quarters. The position peaked at $13K in Q1 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Quadrant Capital Group reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 4,853 Allogene Therapeutics shares in Q2 2026, an estimated $11.8K.
  • Quadrant Capital Group first reported a position in Allogene Therapeutics in Q2 2021 and held it in 17 quarters.
  • Quadrant Capital Group's Allogene Therapeutics position peaked at $13K in Q1 2022.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.